<DOC>
	<DOCNO>NCT01221350</DOCNO>
	<brief_summary>The aim study use antioxidant antiinflammatory effect lipoic acid improve quality life patient asthma . The investigator administrate 600 mg lipoic acid orally daily basis two month concurrent patient anti-asthmatic therapy evaluate effect result pulmonary function , inflammatory oxidative stress biomarkers health-related quality life previous initial treatment 60 day supplementary therapy .</brief_summary>
	<brief_title>Effects Lipoic Acid Oxidative , Inflammatory Functional Markers Asthmatic Patients</brief_title>
	<detailed_description>Asthma inflammatory disease high prevalence around world . During development asthma presence oxidative stress relate susceptibility severity disease , thus make use antioxidant adjuvant therapy lipoic acid ( LA ) interest treatment option . The objective study evaluate efficacy LA adjuvant treatment functional , antioxidant , inflammatory , quality control parameter asthma human subject . The trial design randomize , double blind , placebo control parallel study . Adult patient ( &gt; 18 year ) history mild intermittent moderate asthma accord Global Initiative Asthma ( GINA ) guideline enrol . It require positive skin prick test ( &gt; 3 mm ) least two regional allergen . Patients randomly assign receive lipoic acid placebo 60 day . Participants intermediate visit attend physician one month initial treatment monitor adverse event undergo laboratory test . 1 . Introduction . Asthma inflammatory disease high prevalence around world . During development asthma presence oxidative stress relate susceptibility severity disease , thus make use antioxidant adjuvant therapy lipoic acid ( LA ) interest treatment option . 2 . Study design . A randomized , double blind , placebo control parallel study 3 . Methods . Participants intervention : 55 patient mild moderate asthma Hospital Civil `` Juan I. Menchaca '' Guadalajara , Jalisco , México include randomized block 10 receive ; LA ( 600 mg/day ) placebo eight week January October 2011 . 4 . Objective . To evaluate efficacy LA adjuvant treatment functional , antioxidant , inflammatory , quality control parameter asthma human subject . Primary outcome : change Forced expiratory volume 1 second ( FEV1 ) , secondary outcome level Oxygen radical absorbance capacity ( ORAC ) , glutathione ( GSH ) , glutathione disulfide ( GSSG ) , protein carbonyl , differential count sputum cell , interleukin-4 ( IL-4 ) score quality life control asthma questionnaire .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Thioctic Acid</mesh_term>
	<criteria>Outpatients ( ≥18 ≤ 75 year age ) female male Willingness participate comply procedure sign write informed consent Moderate/severe persistent allergic rhinitis accord Allergic Rhinitis Impact Asthma ( ARIA ) guideline history intermittent , mild persistent moderate persistent asthma accord GINA guideline Confirmed allergy least one follow allergen preparation : house dust mite f ; house dust mite p ; cockroach ; bush mix ; tree mix ; grass mix ; weed mix , cat ; dog . All prior medication washout time observed Female volunteer childbearing potential agree use medically accept method contraception Negative urine pregnancy test Without concomitant chronic medical condition ( e.g. , significant cardiovascular disease , diabetes require medication , chronic kidney disease , chronic thyroid disease , coagulation defect ) Willingness adhere dose visit schedule Pregnant breastfeed Female intend become pregnant study within 12 week study completion Taking medication prohibit study comply requirement designate washout period prohibit medication Anatomical abnormality nose ( turbinate hypertrophy , septal deviation , polyp ) Acute chronic sinusitis currently treat antibiotic and/or topical oral decongestant Upper respiratory tract sinus infection require antibiotic therapy least 14day washout period prior runin period Patients undergoing progressive course immunotherapy . Subjects regular maintenance schedule prior screen visit eligible study inclusion ; however , subject could receive hyposensitization treatment within 24 hour prior study visit Concomitant medical problem In situation condition could interfere participation study Allergic sensitivity study drug excipients History inadequate adherence treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Allergic rhinitis</keyword>
	<keyword>Respiratory disease</keyword>
	<keyword>Allergy</keyword>
	<keyword>Lipoic acid</keyword>
	<keyword>Thioctic acid</keyword>
	<keyword>Antioxidant</keyword>
	<keyword>Oxidative stress</keyword>
</DOC>